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Background: There is a paucity of data on the relative safety and efficacy of different types of DES according to lesion length (LL) and reference 
vessel diameter (RVD), two well known predictors of adverse events after PCI.
Methods: Patient-level data were pooled from the randomized SPIRIT II, III, IV and COMPARE trials comparing the Xience V everolimus-eluting stent 
(EES) and the Taxus paclitaxel-eluting stent (PES). Long lesions and small vessels were defined as LL >median and RVD ≤median, respectively. 2-year 
outcomes according to stent type were examined after PCI in short lesions in large vessels (group A), in either long lesions or small vessels (but not 
both; group B), and in long lesions in small vessels (group C).
Results: QCA data were available for 6,183 patients randomized to EES (n=3,944) or PES (n=2,239). Median RVD was 2.6 mm and median LL was 
13.4 mm. The table shows 2-year outcomes in the 3 groups according to stent randomization. In group A, although the MACE rates were numerically 
less with EES than PES, the differences were not statistically significant. In contrast, in groups B and C EES was associated with lower rates of MACE, 
all its individual components (except cardiac death in group C), and stent thrombosis.
Conclusion: There were no significant differences with EES and PES in patients with short lesions in large vessels. In patients with either long 
lesions, small vessels or both, EES resulted in significant improvements in both safety and efficacy measures.
